

Table I. Activity of 4'-Deoxydaunorubicin (3) and 4'-Deoxyadriamycin (4) on L1210 Leukemia in Mice^a

Compd	Optimal dose ^b	T/C ^c	LST ^d
Daunorubicin	2	162	
3	4	162	
Adriamycin	5	155	2/10
4	4	177	2/10

^a Tumor inoculum 10⁵ cells, ip. ^b Treatment ip on day 1 (mg/kg of body weight). ^c Average survival time expressed as percent of untreated controls. Median survival time of untreated controls was 9 days. ^d Long-term survivors (60 days). No toxic deaths were observed at optimal doses indicated.

Table II. Comparison of 4'-Deoxyadriamycin (4) with Adriamycin on Solid Sarcoma 180 in Mice

Compd	Dose ^a	Tumor growth ^b	T/C ^c
Adriamycin	1.6	52	95
	2	51	184
4	0.8	47	90
	1	46	143

^a Treatment iv on days 1-5 (mg/kg/day). ^b Tumor size evaluated in live animals on day 11 after tumor implant expressed as percent of untreated controls. ^c Average survival time expressed as percent of untreated controls. Median survival time of untreated controls was 22 days.

Acknowledgments. The authors are indebted to A. Di Marco and A. M. Casazza of the Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, for the biological data; to A. Vigevari and B. Gioia for the interpretation of the ¹H NMR and mass spectra; and to A. Alemanni for elemental analysis.

References and Notes

- (1) S. K. Carter, *J. Natl. Cancer Inst.*, **55**, 1265 (1975).
- (2) F. Arcamone, S. Penco, and A. Vigevari, *Cancer Chemother. Rep.*, **6**, 123 (1975).
- (3) F. Arcamone, S. Penco, A. Vigevari, S. Redaelli, G. Franchi, A. Di Marco, A. M. Casazza, T. Dasdia, F. Formelli, A. Necco, and C. Soranzo, *J. Med. Chem.*, **18**, 703 (1975).
- (4) F. Arcamone, A. Bargiotti, G. Cassinelli, S. Penco, and S. Hanessian, *Carbohyd. Res.*, **46**, C3 (1976).
- (5) F. Arcamone, A. Bargiotti, A. Di Marco, and S. Penco, British Patent Application 18098/75 (April 30, 1975); S. Hanessian and J. Banoub, *Carbohyd. Res.*, **44**, C14 (1975), and references cited therein.
- (6) F. Arcamone, G. Franceschi, and S. Penco, U.S. Patent 3803 124 (April 9, 1974).

Federico Arcamone,* Sergio Penco, Silvio Redaelli
Farmitalia, Ricerca Chimica, Milano, Italy

Stephen Hanessian
Department of Chemistry, University of Montreal
Montreal, Quebec, Canada

Received June 23, 1976

Additions and Corrections

1968, Volume 11

Girgis M. Bebawi and J. P. Lambooy: Synthesis of Substituted 4-Dimethylaminoazobenzenes and a Study of Their Effect on *Lactobacillus casei* and *Escherichia coli*.

Page 580. In column 2, line 1, "certainty on complete" should read certainty or complete.

Page 581. In Table I under Composition, the sixth formula should be C₁₇H₂₁N₃, the seventh formula C₁₇H₂₁N₃, and the eighth formula C₁₈H₂₃N₃.

1975, Volume 18

W. J. Wechter, M. A. Johnson, C. M. Hall, D. T. Warner, A. E. Berger, A. H. Wenzel, D. T. Gish, and G. L. Neil: *ara*-Cytidine Acylates. Use of Drug Design Predictors in Structure-Activity Relationship Correlation.

Page 342. In column 2, line 23 should read law ($A = Ebc$, where A is the absorbance, E the molar extinction coefficient, etc.). In line 27, the equation should read

$$P = c_{O/W}/c_{W/O} = \frac{(A_O)(E_W b_W)}{(A_W)(E_O b_O)}$$

In line 29, the equation should read

$$P = A_O E_W / A_W E_O$$

Norman J. Santora and King Auyang: Non-Computer Approach to Structure-Activity Study. An Expanded Fibonacci Search Applied to Structurally Diverse Types of Compounds.


Page 960. In column 2, line 1, "point number 19" should read point number 14.

Arthur A. Santilli, Anthony C. Scotese, and John A. Yurchenco: Synthesis and Antibacterial Evaluation of 1,2,3,4-Tetrahydro-4-oxo-1,8-naphthyridine-3-carboxylic Acid Esters, Carbonitriles, and Carboxamides.

Page 1041. To ref 7 should be added, A. A. Santilli and A. C. Scotese, U.S. Patent 3853 864 (1974), which specifically describes the preparation of methyl 2-chloro-6-methylnicotinate.

Gilda H. Loew and J. Randal Jester: Quantum Chemical Studies of Meperidine and Prodine.

Page 1054. Figures 4 and 5 are mistakenly identical. While the captions of each are correct, Figure 4 itself is wrong. Below is the correct Figure 4.




meperidine

1976, Volume 19

Ping-Lu Chien and C. C. Cheng: Difference in Antimalarial Activity between Certain Amino Alcohol Diastereomers.

Page 170. In column 1, structure I is incorrectly represented. The correct structure is



Steven D. Wyrick, Iris H. Hall, C. Piantadosi, and Charles R. Fenske: Cycloalkanones. 8. Hypocholesterolemic Activity of Long-Chain Ketones Related to Pentadecanone.

Page 220. In Table I, the formulas for structures 5 and 7 should be reversed: 5 should be $C_{16}H_{32}O$ and 7, $C_{18}H_{36}O$.


M. M. Hashem, K. D. Berlin, R. W. Chesnut, and N. N. Durham: Novel Pyrazolo, Isoxazolo, and Thiazolo Steroidal Systems and Model Analogs Containing Dimethoxylaryl (or Dihydroxylaryl) Groups and Derivatives. Synthesis, Spectral Properties, and Biological Activity.

Page 233. In column 2, last line, "the [1,2-*d*] isomer" should read the [1,2-*c*] isomer.

Page 234. In column 2, line 1, "experiences a shielding effect" should read experiences a deshielding effect. In Scheme IV, the unnumbered structure is missing an R group at the 2 position.

E. A. Mawdsley, K. D. Berlin, R. W. Chesnut, and N. N. Durham: Synthesis and Structure-Activity Relationships of Heterocyclic Compounds Containing a Trimethoxyarene Function.


Page 239. In Scheme I, the side chain in structure 3 is misplaced; it should be



3

Also in Scheme I, the structure in the lower right corner should be labeled compound 2.

Page 240. In structure 17 the double bonds are incorrectly positioned; the correct structure should be




17

Page 241. In column 2, second paragraph, line 25, "5 (mp 123-127°)" should read 4 (mp 123-127°). In the same paragraph, line 33, "(32.5% from 5)" should read (32.5% from 3).

B. Paul and W. Korytnyk: Cysteine Derivatives with Reactive Groups as Potential Antitumor Agents.

Page 1003. In structure VI the stereochemistry has been incorrectly represented on two carbon atoms. It should be



VI